Literature DB >> 19830433

Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis.

Athina Pyrpasopoulou1, Stella Douma, Themistoklis Vassiliadis, Sofia Chatzimichailidou, Areti Triantafyllou, Spyros Aslanidis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19830433     DOI： 10.1007/s00296-009-1202-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  10 in total

Review 1.  Reactivation of hepatitis B virus with rituximab.

Authors:  Yutaka Tsutsumi; Hiroe Kanamori; Akio Mori; Junji Tanaka; Masahiro Asaka; Masahiro Imamura; Nobuo Masauzi
Journal:  Expert Opin Drug Saf       Date:  2005-05       Impact factor: 4.250

2.  Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab.

Authors:  Toshiki Sera; Yoichi Hiasa; Kojiro Michitaka; Ichiro Konishi; Kana Matsuura; Yoshio Tokumoto; Bunzo Matsuura; Takeshi Kajiwara; Toshikazu Masumoto; Norio Horiike; Morikazu Onji
Journal:  Intern Med       Date:  2006-07-03       Impact factor: 1.271

Review 3.  Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach.

Authors:  Debbie M Nathan; Peter W Angus; Peter R Gibson
Journal:  J Gastroenterol Hepatol       Date:  2006-09       Impact factor: 4.029

4.  Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.

Authors:  W Yeo; P K Chan; S Zhong; W M Ho; J L Steinberg; J S Tam; P Hui; N W Leung; B Zee; P J Johnson
Journal:  J Med Virol       Date:  2000-11       Impact factor: 2.327

5.  Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.

Authors:  C H Roux; O Brocq; V Breuil; C Albert; L Euller-Ziegler
Journal:  Rheumatology (Oxford)       Date:  2006-04-07       Impact factor: 7.580

6.  Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

Authors:  Winnie Yeo; Tung C Chan; Nancy W Y Leung; Wai Y Lam; Frankie K F Mo; Miu Ting Chu; Henry L Y Chan; Edwin P Hui; Kenny I K Lei; Tony S K Mok; Paul K S Chan
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

Review 7.  Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.

Authors:  L H Calabrese; N Zein; D Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

8.  Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases.

Authors:  S Zingarelli; P Airò; M Frassi; C Bazzani; M Scarsi; M Puoti
Journal:  Reumatismo       Date:  2008 Jan-Mar

Review 9.  The risk of infections with biologic therapies for rheumatoid arthritis.

Authors:  Daniel E Furst
Journal:  Semin Arthritis Rheum       Date:  2008-12-31       Impact factor: 5.532

Review 10.  Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.

Authors:  C Salliot; M Dougados; L Gossec
Journal:  Ann Rheum Dis       Date:  2008-01-18       Impact factor: 19.103
  10 in total
  24 in total

Review 1.  Complications of long-term therapy for ANCA-associated systemic vasculitis.

Authors:  Nadezhda Wall; Lorraine Harper
Journal:  Nat Rev Nephrol       Date:  2012-06-05       Impact factor: 28.314

2.  [Recommendations for use of rituximab in patients with rheumatoid arthritis].

Authors:  A Rubbert-Roth; G R Burmester; T Dörner; A Gause
Journal:  Z Rheumatol       Date:  2014-03       Impact factor: 1.372

Review 3.  A comprehensive review of rituximab therapy in rheumatoid arthritis patients.

Authors:  Soheil Tavakolpour; Samira Alesaeidi; Mohammad Darvishi; Mojtaba GhasemiAdl; Sahar Darabi-Monadi; Meisam Akhlaghdoust; Somayeh Elikaei Behjati; Arash Jafarieh
Journal:  Clin Rheumatol       Date:  2019-08-01       Impact factor: 2.980

Review 4.  Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.

Authors:  Francesca De Nard; Monica Todoerti; Vittorio Grosso; Sara Monti; Silvia Breda; Silvia Rossi; Carlomaurizio Montecucco; Roberto Caporali
Journal:  World J Hepatol       Date:  2015-03-27

5.  Prevalence of hepatitis B and C infections in rheumatoid arthritis and ankylosing spondylitis: A multicenter countrywide study.

Authors:  Neslihan Yılmaz; Ömer Karadağ; Gezmiş Kimyon; Ayten Yazıcı; Sema Yılmaz; Umut Kalyoncu; Timuçin Kaşifoğlu; Hakan Temiz; Birol Baysal; Nurdan Tözün
Journal:  Eur J Rheumatol       Date:  2014-06-01

Review 6.  Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

Authors:  Shunsuke Mori; Shigetoshi Fujiyama
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

7.  Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines?

Authors:  Jinoos Yazdany; Leonard Calabrese
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-05       Impact factor: 4.794

8.  Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.

Authors:  Akihiro Tamori; Tatsuya Koike; Hitoshi Goto; Shigeyuki Wakitani; Masahiro Tada; Hiroyasu Morikawa; Masaru Enomoto; Masaaki Inaba; Tatsuya Nakatani; Masayuki Hino; Norifumi Kawada
Journal:  J Gastroenterol       Date:  2011-01-19       Impact factor: 7.527

Review 9.  Management of rheumatic disease with comorbid HBV or HCV infection.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Nat Rev Rheumatol       Date:  2012-05-08       Impact factor: 20.543

10.  [Secondary immunodeficiency in rheumatological diseases].

Authors:  D Ernst; R E Schmidt; T Witte
Journal:  Z Rheumatol       Date:  2013-09       Impact factor: 1.372
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.